2024-08-25 - Analysis Report
## JNJ Stock Analysis

### Company Overview

JNJ stands for Johnson & Johnson, a multinational pharmaceutical, medical device, and consumer goods company. JNJ is known for its diverse product portfolio, including over-the-counter medications, prescription drugs, medical devices, and consumer healthcare products. 

### Performance Analysis

**1. Relative Performance:**

* **Cumulative Return:** JNJ has a cumulative return of 23.45%, while the S&P 500 (VOO) has a cumulative return of 71.75%. 
* **Relative Lag:** JNJ lags behind the S&P 500 by 48.34%. This represents a relative performance of 14.39% in the context of historical data.

**2. Recent Price Movements:**

* **Closing Price:** $164.13
* **5-day Moving Average:** $161.54
* **20-day Moving Average:** $160.28
* **60-day Moving Average:** $152.70

JNJ is currently trading above its short-term moving averages, indicating a bullish trend, but below its long-term moving average, suggesting potential room for further growth. 

**3. Technical Indicators:**

* **RSI:** 66.89. This suggests JNJ is in the overbought territory.
* **PPO:** -0.02. This indicates a weak momentum, potentially signaling a reversal.
* **Delta_Previous_Relative_Divergence:** -2.79. This negative value reflects a short-term decline in relative performance.

**4. Recent Earnings and Outlook:**

| Date       | EPS      | Revenue     |
|------------|----------|-------------|
| 2024-07-25 | 1.95     | 22.45 B$   |
| 2024-05-01 | 1.35     | 21.38 B$   |
| 2024-02-16 | 1.68     | 21.39 B$   |
| 2023-10-27 | 10.32    | 21.35 B$   |
| 2024-02-16 | 10.32    | 21.35 B$   |

The most recent earnings report for Q2 2024 shows EPS of $1.95, surpassing analyst estimates. Revenue also came in above expectations, demonstrating strong performance. However, the company's outlook for future quarters is unclear and needs to be monitored closely.

### Overall Analysis

JNJ is currently trading in a bullish trend, but the overbought RSI and negative PPO indicate potential for a correction. Although recent earnings beat estimates, future performance and outlook remain unclear. The company's relative underperformance compared to the S&P 500 highlights the need for careful consideration before investing. Further research into JNJ's specific segments, competitive landscape, and future growth strategies is crucial for making informed investment decisions. 
